X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (159) 159
Publication (24) 24
Newspaper Article (16) 16
Conference Proceeding (4) 4
Book / eBook (3) 3
Book Chapter (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (81) 81
oncology (72) 72
female (71) 71
index medicus (67) 67
breast neoplasms - drug therapy (45) 45
breast cancer (42) 42
middle aged (40) 40
adult (35) 35
breast neoplasms - pathology (33) 33
aged (32) 32
treatment outcome (23) 23
article (20) 20
cancer (20) 20
research (17) 17
breast neoplasms - metabolism (16) 16
animals (15) 15
care and treatment (15) 15
chemotherapy (15) 15
trastuzumab (14) 14
medicine (13) 13
prognosis (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
breast neoplasms - genetics (12) 12
health aspects (12) 12
metastasis (12) 12
neoplasm staging (12) 12
receptor, erbb-2 - metabolism (12) 12
therapy (12) 12
analysis (11) 11
antineoplastic agents - therapeutic use (11) 11
male (11) 11
breast neoplasms - mortality (10) 10
disease-free survival (10) 10
research article (10) 10
women (10) 10
aged, 80 and over (9) 9
breast-cancer (9) 9
chemotherapy, adjuvant (9) 9
medicine & public health (9) 9
neoadjuvant therapy (9) 9
radiology, nuclear medicine & medical imaging (9) 9
studies (9) 9
survival (9) 9
breast neoplasms - therapy (8) 8
cell line, tumor (8) 8
endocrine therapy (8) 8
estrogen (8) 8
genomes (8) 8
hyperthermia (8) 8
neoplasm metastasis (8) 8
outcomes (8) 8
quality of life (8) 8
risk factors (8) 8
solid tumors (8) 8
tumors (8) 8
abridged index medicus (7) 7
clinical trials (7) 7
combination (7) 7
combined modality therapy (7) 7
diagnosis (7) 7
double-blind method (7) 7
drug therapy (7) 7
endothelial growth-factor (7) 7
expression (7) 7
kaplan-meier estimate (7) 7
mice (7) 7
patients (7) 7
postmenopausal women (7) 7
recurrence (7) 7
resistance (7) 7
safety (7) 7
skin and connective tissue diseases (7) 7
adjuvant chemotherapy (6) 6
antibodies, monoclonal, humanized (6) 6
double-blind (6) 6
gene expression (6) 6
genetic aspects (6) 6
growth (6) 6
hematology, oncology and palliative medicine (6) 6
her2 (6) 6
hypoxia (6) 6
letrozole (6) 6
multicenter (6) 6
mutation (6) 6
quality-of-life (6) 6
quinazolines - therapeutic use (6) 6
review (6) 6
surgery (6) 6
usage (6) 6
antineoplastic agents - adverse effects (5) 5
apoptosis (5) 5
biomarkers, tumor - metabolism (5) 5
distant metastases (5) 5
doxorubicin - administration & dosage (5) 5
drug resistance, neoplasm (5) 5
drug therapy, combination (5) 5
epidermal growth factor (5) 5
erbb-2 protein (5) 5
gene-expression (5) 5
immunohistochemistry (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
OISE - Stacks (2) 2
Robarts - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
New College (Ivey) - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pediatrics, ISSN 0031-4005, 03/2016, Volume 137, Issue 3, p. 1
  There is growing interest in the relationship between dietary habits and cancer. Dietary fibers are a complex group of oligosaccharides, polysaccharides,... 
Menopause | Breast cancer | Dietary fiber | Risk factors
Journal Article
Targeted Oncology, ISSN 1776-2596, 2/2019, Volume 14, Issue 1, pp. 1 - 12
Fulvestrant is recommended for patients with hormone receptor-positive (HR+) advanced breast cancer (ABC) who progress after aromatase inhibitor therapy. As... 
Biomedicine, general | Medicine & Public Health | Oncology | ONCOLOGY | PROGRESSION-FREE SURVIVAL | TAMOXIFEN RESISTANCE | DOUBLE-BLIND | CDK4/6 INHIBITION | ESR1 MUTATIONS | ENDOCRINE THERAPY | CLINICAL ONCOLOGY | MECHANISMS | ESTROGEN-RECEPTOR | 500 MG | Care and treatment | Breast cancer | Epidermal growth factor | Resveratrol | Fulvestrant | Review
Journal Article
Targeted Oncology, ISSN 1776-2596, 2/2019, Volume 14, Issue 1, pp. 13 - 13
The article Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer, written by Sarah Sammons, Noah... 
Biomedicine, general | Medicine & Public Health | Oncology | Care and treatment | Breast cancer | Resveratrol | Fulvestrant
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e12527 - e12527
Journal Article
Breast, The, ISSN 0960-9776, 2013, Volume 22, pp. S24 - S24
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e12075 - e12075
Journal Article
Targeted oncology, 12/2018
The article Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer, written by Sarah Sammons, Noah... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 21, pp. e371 - e371
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2008, Volume 112, Issue S1, pp. 35 - 43
Journal Article
Journal Article
The Breast, ISSN 0960-9776, 2008, Volume 17, pp. S1 - S2
Journal Article
Breast, ISSN 0960-9776, 01/2008, Volume 17, Issue 1, pp. S1 - S2
Journal Article
Breast, The, ISSN 0960-9776, 2008, Volume 17, pp. S1 - S2
Journal Article
The Breast, ISSN 0960-9776, 01/2008, Volume 17, pp. S1 - S2
Journal Article
Current Cancer Drug Targets, ISSN 1568-0096, 2017, Volume 17, Issue 7, pp. 637 - 649
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone... 
Ribociclib | Abemaciclib | Advanced breast cancer | Hormone receptor-positive | Palbociclib | CDK4/6 inhibitor | SOLID TUMORS | ENDOCRINE THERAPY | RANDOMIZED CONTROLLED-TRIAL | CELL-CYCLE CONTROL | COMBINATION | DEPENDENT KINASE 4/6 | hormone receptor-positive | ONCOLOGY | FEBRILE NEUTROPENIA | advanced breast cancer | palbociclib | PHASE-I | PD 0332991 | ribociclib | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Liver - enzymology | Pyridines - administration & dosage | Purines - pharmacology | Humans | Receptor, ErbB-2 - metabolism | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Transcription Factors - metabolism | Liver - drug effects | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Aminopyridines - pharmacology | Benzimidazoles - pharmacology | Female | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Molecular Targeted Therapy - methods | Therapy | Cyclin-dependent kinases | Endocrine therapy | Breast cancer | Kinases | ErbB-2 protein | Cyclin-dependent kinase 4 | Manuscripts | Mode of action | Cyclin-dependent kinase | Side effects | Epidermal growth factor | Inhibitors | Breast | Safety | Monitoring | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.